146 related articles for article (PubMed ID: 10389768)
1. Functional reassessment of P16 variants using a transfection-based assay.
Walker GJ; Gabrielli BG; Castellano M; Hayward NK
Int J Cancer; 1999 Jul; 82(2):305-12. PubMed ID: 10389768
[TBL] [Abstract][Full Text] [Related]
2. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
3. CDKN2A/p16 is inactivated in most melanoma cell lines.
Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
[TBL] [Abstract][Full Text] [Related]
4. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
[TBL] [Abstract][Full Text] [Related]
5. Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation.
Scaini MC; Rossi E; de Siqueira Torres PL; Zullato D; Callegaro M; Casella C; Quaggio M; Agata S; Malacrida S; Chiarion-Sileni V; Vecchiato A; Alaibac M; Montagna M; Mann GJ; Menin C; D'Andrea E
Mutat Res; 2009 Dec; 671(1-2):26-32. PubMed ID: 19712690
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
[TBL] [Abstract][Full Text] [Related]
7. Restoration of CDKN2A into melanoma cells induces morphologic changes and reduction in growth rate but not anchorage-independent growth reversal.
Castellano M; Gabrielli BG; Hussussian CJ; Dracopoli NC; Hayward NK
J Invest Dermatol; 1997 Jul; 109(1):61-8. PubMed ID: 9204956
[TBL] [Abstract][Full Text] [Related]
8. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
[TBL] [Abstract][Full Text] [Related]
9. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
10. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
11. A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare.
Kumar R; Smeds J; Berggren P; Straume O; Rozell BL; Akslen LA; Hemminki K
Int J Cancer; 2001 Nov; 95(6):388-93. PubMed ID: 11668523
[TBL] [Abstract][Full Text] [Related]
12. Alteration of CDKN2/p16 in human astrocytic tumors is related with increased susceptibility to antimetabolite anticancer agents.
Iwadate Y; Mochizuki S; Fujimoto S; Namba H; Sakiyama S; Tagawa M; Yamaura A
Int J Oncol; 2000 Sep; 17(3):501-5. PubMed ID: 10938390
[TBL] [Abstract][Full Text] [Related]
13. A novel CDKN2A variant (p16
Li C; Liu T; Liu B; Hernandez R; Facelli JC; Grossman D
Pigment Cell Melanoma Res; 2019 Sep; 32(5):734-738. PubMed ID: 31001908
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
[TBL] [Abstract][Full Text] [Related]
15. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1.
Zhang S; Ramsay ES; Mock BA
Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2429-34. PubMed ID: 9482902
[TBL] [Abstract][Full Text] [Related]
16. Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention.
Fan M; Pfeffer SR; Lynch HT; Cassidy P; Leachman S; Pfeffer LM; Kopelovich L
Oncotarget; 2013 Jan; 4(1):128-41. PubMed ID: 23371019
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
[TBL] [Abstract][Full Text] [Related]
18. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas.
Harada H; Nakagawa K; Iwata S; Saito M; Kumon Y; Sakaki S; Sato K; Hamada K
Cancer Res; 1999 Aug; 59(15):3783-9. PubMed ID: 10446996
[TBL] [Abstract][Full Text] [Related]
19. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.
Parry D; Peters G
Mol Cell Biol; 1996 Jul; 16(7):3844-52. PubMed ID: 8668202
[TBL] [Abstract][Full Text] [Related]
20. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
Horn IP; Marks DL; Koenig AN; Hogenson TL; Almada LL; Goldstein LE; Romecin Duran PA; Vera R; Vrabel AM; Cui G; Rabe KG; Bamlet WR; Mer G; Sicotte H; Zhang C; Li H; Petersen GM; Fernandez-Zapico ME
J Biol Chem; 2021; 296():100634. PubMed ID: 33823155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
